CA3129250A1 - Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes - Google Patents

Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes Download PDF

Info

Publication number
CA3129250A1
CA3129250A1 CA3129250A CA3129250A CA3129250A1 CA 3129250 A1 CA3129250 A1 CA 3129250A1 CA 3129250 A CA3129250 A CA 3129250A CA 3129250 A CA3129250 A CA 3129250A CA 3129250 A1 CA3129250 A1 CA 3129250A1
Authority
CA
Canada
Prior art keywords
cancer
microbial
patient
exosomes
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129250A
Other languages
English (en)
French (fr)
Inventor
Raghu Kalluri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3129250A1 publication Critical patent/CA3129250A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3129250A 2019-02-08 2020-02-07 Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes Pending CA3129250A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802994P 2019-02-08 2019-02-08
US62/802,994 2019-02-08
PCT/US2020/017224 WO2020163724A1 (en) 2019-02-08 2020-02-07 Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes

Publications (1)

Publication Number Publication Date
CA3129250A1 true CA3129250A1 (en) 2020-08-13

Family

ID=71947984

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129250A Pending CA3129250A1 (en) 2019-02-08 2020-02-07 Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes

Country Status (8)

Country Link
US (1) US20220137056A1 (https=)
EP (1) EP3921325A4 (https=)
JP (1) JP2022519326A (https=)
KR (1) KR20210125532A (https=)
CN (1) CN113631725A (https=)
AU (1) AU2020218358A1 (https=)
CA (1) CA3129250A1 (https=)
WO (1) WO2020163724A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4373976A4 (en) * 2021-07-20 2025-06-18 Liquid Biopsy Holdco, LLC METHODS FOR DIAGNOSIS OF DISEASE USING MICROBIAL EXTRACELLULAR VESICLE (MEV) ANALYTES

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
WO2021158966A1 (en) 2020-02-05 2021-08-12 Board Of Regents, The University Of Texas System Diagnostic and prognostic utility of exosomes in immunotherapy
CN114486829B (zh) * 2022-01-24 2023-06-27 复旦大学 一种微量外泌体捕集并计数的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807045D0 (en) * 1998-04-01 1998-06-03 Rudi Knut Nucleic acid detection method
KR101810799B1 (ko) * 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2011027956A2 (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
CA2846804A1 (en) * 2011-08-26 2013-03-07 Microbiota Diagnostics, Llc Methods for diagnosing and treating cardiac defects
US20150176073A1 (en) * 2012-07-18 2015-06-25 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
US9921223B2 (en) * 2013-12-04 2018-03-20 Board Of Regents, The University Of Texas System Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis
KR101798176B1 (ko) * 2014-12-16 2017-11-15 주식회사 엠디헬스케어 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법
KR101726488B1 (ko) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US10526665B2 (en) * 2016-03-04 2020-01-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis
JP2018063182A (ja) * 2016-10-13 2018-04-19 国立大学法人 新潟大学 腸内細菌の菌叢分析方法及び被検体におけるヘリコバクター・ピロリに対するアレルギーの検出方法
KR20180076308A (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
WO2018124618A1 (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
WO2018124735A1 (ko) * 2016-12-28 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
AU2018239339A1 (en) * 2017-03-23 2019-10-03 Penn State Research Foundation Method for diagnosing or monitoring conditions characterized by abnormal temporal variations method of normalizing epigenetic data to compensate for temporal variations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4373976A4 (en) * 2021-07-20 2025-06-18 Liquid Biopsy Holdco, LLC METHODS FOR DIAGNOSIS OF DISEASE USING MICROBIAL EXTRACELLULAR VESICLE (MEV) ANALYTES

Also Published As

Publication number Publication date
EP3921325A4 (en) 2022-11-23
CN113631725A (zh) 2021-11-09
JP2022519326A (ja) 2022-03-22
EP3921325A1 (en) 2021-12-15
KR20210125532A (ko) 2021-10-18
AU2020218358A1 (en) 2021-08-26
US20220137056A1 (en) 2022-05-05
WO2020163724A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
US20220137056A1 (en) Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes
JP5416110B2 (ja) ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法
JP2010536372A5 (https=)
WO2012149609A1 (en) A method of diagnosing neoplasms
Tong et al. Diagnostic test to Identify Parkinson’s disease from the blood sera of Chinese population: A cross‐sectional study
WO2018213392A1 (en) Microvesicle nucleic acids and/or proteins and uses thereof as markers of renal transplant rejection
JP6531987B2 (ja) 腎疾患診断のためのエクソソーム回収法
Zhao et al. HMGA1 influence on iron-induced cell death in Tfh cells of SLE patients
US20250075258A1 (en) Methods of detecting sjogren's syndrome using salivary exosomes
CN107583052B (zh) miR-6734-5p在制备Luminal型乳腺癌诊断工具中的应用
CN105950705B (zh) 一组microRNAs在制备阿尔兹海默氏症诊断试剂或诊断试剂盒中的应用
US11718878B2 (en) Exosome profiling for diagnosis and monitoring of vasculitis and vasculopathies including Kawasaki disease
JP7802367B2 (ja) 膵臓がんのバイオマーカーとしてのマイクロｒｎａの使用
US20170211139A1 (en) Compositions and methods for detecting rare sequence variants in nucleic acid sequencing
Mahboobi et al. Evolution of miR-155 and its probable targets: MST1R, Adam10, and CD9 genes expression levels in adults and children gastritis patients with H. pylori infection
CN120550120A (zh) 抑制cd4+t细胞衰老在制备减缓老年溃疡性结肠炎进展药物中的应用
CN118326035A (zh) 一种血浆外泌体pir-56497的检测方法及其应用
CN110885885A (zh) 阿尔茨海默病诊治用基因标志物
CN114107491A (zh) Muc22基因启动子区相关的组蛋白修饰分析引物对及检测试剂盒
CN111363808A (zh) 一种与阿尔茨海默相关的生物标志物及其应用
Mallawaaratchy et al. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive
HK1218767B (zh) 使用mirna检测体内细胞死亡情况的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250716

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260323